Pharmacogenetics of Remifentanil in Patients With Hypertension Undergoing Cesarean Delivery Under General Anesthesia
Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
Caesarean delivery under general anaesthesia (GA) carries nowadays still 25% risk of
insufficient depth of anaesthesia in a time before the fetus delivery. The reason is the lack
of opioid administration. Opioids easily cross placental barrier and negatively influence
newborn postpartum adaptation by respiratory depression. Introduction to GA is thus
accompanied by exaggerated autonomic stress reaction with hypertension and tachycardia. The
use of ultra-short acting opioid remifentanil should suppress stress response in mother
without increasing the risk for newborn. There are only a few clinical data available. This
study will be the first one systematically studying the influence of remifentanil in pregnant
women with hypertension on hemodynamic stability and newborns safety. This study will also
identify potential pharmacogenetic factors of individual variability in remifentanil response
with respect of drug efficacy and safety in mother and newborn.